natgillin/translations-raw huggingface dataset:
When initiating Levodopa/Carbidopa/Entacapone Orion therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Levodopa/Carbidopa/Entacapone Orion 150 mg/37.5 mg/200 mg (or 50 mg/12.5 mg/200 mg, or 75 mg/18.75 mg/200 mg or
Ob uvajanju terapije z zdravilom Levodopa/Carbidopa/Entacapone Orion pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Levodopa/Carbidopa/Entacapone Orion 150 mg/37,5 mg/200 mg (ali 50 mg/12,5 mg/200 mg ali
When initiating Levodopa/Carbidopa/Entacapone Orion therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg (or 50 mg/12.5 mg/200 mg or 75 mg/18.75 mg/200 mg or
Ob uvajanju terapije z zdravilom Levodopa/Carbidopa/Entacapone Orion pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg (ali 50 mg/12,5 mg/200 mg ali
When initiating Lucentis therapy, caution should be used in patients with these risk factors for retinal pigment epithelial tears.
Pri uvajanju zdravila Lucentis bolnikom z navedenimi dejavniki tveganja za raztrganje pigmentnega epitelija mrežnice je potrebna previdnost.
When initiating Stalevo in patients currently treated with entacapone and levodopa/benserazide in a standard release formulation, the dosing of levodopa/benserazide should be discontinued in the previous night, and Stalevo should be started in the next morning.
Ko se zdravljenje z zdravilom Stalevo uvaja pri bolnikih, ki trenutno prejemajo entakapon in levodopo/benzerazid s standardnim sproščanjem, je treba odmerjanje levodope/benzerazida eno noč ukiniti in naslednje jutro začeti dajati zdravilo Stalevo.
When initiating Stalevo in patients currently treated with entacapone and levodopa/benserazide in a standard release formulation, thedosing of levodopa/benserazide should be discontinued in the previous night, and Stalevo should be started in the next morning.
Ko se zdravljenje z zdravilom Stalevo uvaja pri bolnikih, ki trenutno prejemajo entakapon in levodopo/benzerazid s standardnim sproščanjem, je treba odmerjanje levodope/benzerazida eno noč ukiniti in naslednje jutro začeti dajati zdravilo Stalevo.
When initiating Stalevo therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Stalevo 100 mg/25 mg/200 mg (or 50 mg/12.5 mg/200 mg or 75 mg/18.75 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or
Ob uvajanju terapije z zdravilom Stalevo pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Stalevo 100 mg/25 mg/200 mg (ali 50 mg/12,5 mg/200 mg ali 75 mg/18,75 mg/200 mg ali 125 mg/31,25 mg/200 mg ali
When initiating Stalevo therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Stalevo 150 mg/37.5 mg/200 mg (or 50 mg/12.5 mg/200 mg, or 75 mg/18.75 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or
Ob uvajanju terapije z zdravilom Stalevo pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Stalevo 150 mg/37,5 mg/200 mg (ali 50 mg/12,5 mg/200 mg ali 75 mg/18,75 mg/200 mg ali 125 mg/31,25 mg/200 mg ali
When initiating Stalevo therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Stalevo 200 mg/50 mg/200 mg (or 50 mg/12.5 mg/200 mg or 75 mg/18.75 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or
Ob uvajanju terapije z zdravilom Stalevo pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Stalevo 200 mg/50 mg/200 mg (ali 50 mg/12,5 mg/200 mg ali 75 mg/18,75 mg/200 mg ali 100 mg/25 mg/200 mg ali
When initiating Stalevo therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Stalevo 50 mg/12.5 mg/200 mg (or 75 mg/18.75 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or
Ob uvajanju terapije z zdravilom Stalevo pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Stalevo 50 mg/12,5 mg/200 mg (ali 75 mg/18,75 mg/200 mg ali 100 mg/25 mg/200 mg ali 125 mg/31,25 mg/200 mg ali
When initiating Stalevo therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Stalevo 75 mg/18.75 mg/200 mg (or 50 mg/12.5 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or
Ob uvajanju terapije z zdravilom Stalevo pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Stalevo 75 mg/18,75 mg/200 mg (ali 50 mg/12,5 mg/200 mg ali 100 mg/25 mg/200 mg ali 125 mg/31,25 mg/200 mg ali
When initiating treatment with Zoledronic acid Actavis in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined.
Ob uvedbi zdravila Zoledronska kislina Actavis pri bolnikih z multiplim mielomom ali metastatskimi kostnimi lezijami zaradi parenhimskih tumorjev je treba določiti serumski kreatinin in očistek kreatinina (CLcr).
When initiating treatment with zoledronic acid in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined.
Pri uvajanju zdravljenja z zoledronsko kislino pri bolnikih z multiplim mielomom ali metastatičnimi kostnimi lezijami zaradi čvrstih tumorjev je treba določiti vrednosti serumskega kreatinina in očistka kreatinina (CLcr).
When initiating treatment with Zoledronic acid Teva in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined.
Pri uvajanju zdravljenja z zdravilom Zoledronska kislina Teva pri bolnikih z multiplim mielomom ali metastatičnimi kostnimi lezijami zaradi čvrstih tumorjev je treba določiti serumski kreatinin in očistek kreatinina (CLcr).
When initiating treatment with Zometa in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined.
Pri uvajanju zdravljenja z zdravilom Zometa pri bolnikih z multiplim mielomom ali metastatičnimi kostnimi lezijami zaradi čvrstih tumorjev je treba določiti serumski kreatinin in očistek kreatinina (CLcr).
When initiating voriconazole in patients already on ciclosporin it is recommended
Kadar se pri bolnikih, ki že dobivajo ciklosporin, vpelje vorikonazol, je odmerek
When initiating voriconazole in patients already receiving omeprazole doses of 40 mg or above, it is recommended that the omeprazole dose be halved.
odmerku 40 mg ali več, vpelje vorikonazol, je odmerek omeprazola priporočljivo prepoloviti.
When initiating, adjusting, and discontinuing telmisartan, monitor digoxin levels in order to maintain levels within the therapeutic range.
Med uvajanjem telmisartana, prilagajanjem njegovega odmerka in ukinjanjem zdravljenja je treba spremljati koncentracijo digoksina in paziti, da ostane znotraj terapevtskega območja
When injected directly into a muscle it reduces the release of acetylcholine and muscle contraction in the affected neck or shoulder muscles, thereby relieving the patient’s symptoms.
Če je injiciran neposredno v mišico, zmanjša sproščanje acetilholina ter krčenje prizadetih mišic v vratu ali ramenih, kar pomaga ublažiti bolnikove simptome.
When injected under the skin, the recommended dose is 162 mg once every week.
Pri injiciranju v podkožje je priporočeni odmerek 162 mg enkrat na teden.
When injected, this exposure helps the calf’s immune system to recognise and fight the IBR virus.
Ko se injicira, to izpostavljanje pomaga imunskemu sistemu teleta prepoznati IBR virus in se proti njemu bojevati.
When injected, this small exposure helps the cat’s immune system to recognise and attack the viruses and bacterium.
Z injiciranjem zdravila izpostavimo mačko tem majhnim količinam, kar imunskemu sistemu mačke pomaga prepoznavati in napadati viruse in bakterijo.
When injected, this small exposure helps the dog’s immune system to synthesize antibodies against the canine herpes virus and to neutralize it.
Pri vbrizganju pride do šibke izpostavitve virusu, ki imunskemu sistemu pomaga pri tvorjenju protiteles proti pasjemu herpesvirusu in s tem tudi pri njegovi nevtralizaciji.
When injecting Orgalutran in the afternoon the last Orgalutran injection should be given in the afternoon prior to the day of triggering ovulation.
Če pa zdravilo Orgalutran injicirate popoldne, dajte zadnjo injekcijo zdravila Orgalutran popoldne, dan pred sprožitvijo ovulacije.
When injecting regularly, the injection site should be changed between different areas of the body to help reduce potential pain and irritation
Pri rednem injiciranju morate mesto injiciranja menjavati med različnimi predeli telesa, da zmanjšate morebitno bolečino in draženje.
When Innovax-ILT is given to chickens, the animals’ immune system recognises the virus as ‘foreign’ and makes antibodies against it.
Ko piščanci prejmejo cepivo Innovax-ILT, imunski sistem živali prepozna virus kot „tujek“ ter začne proti njemu tvoriti protitelesa.
When Innovax-ILT is mixed with Nobilis Rismavac the development of immunity towards ILT may be delayed in animals with maternally derived antibodies.
Kadar se Innovax-ILT meša s cepivom Nobilis Rismavac, se razvoj imunosti za ILT lahko zakasni pri živalih z maternalnimi protitelesi.
When insulin comes out of the needle tip, your pen is working correctly.
Če iz konice igle pride insulin, peresnik deluje pravilno.
When insulin glulisine is injected subcutaneously, the glucose lowering activity will begin within 10 – 20 minutes.
Po subkutanem injiciranju insulina glulisin se učinek na zniževanje glukoze pojavi v 10 do 20 minutah.
when invasive tests cannot be performed, or when there are discordant results arising from invasive tests.
kadar invazivnih testov ni mogoče izvesti, ali kadar so rezultati invazivnih testov protislovni.
When IPSS cytogenetic subgroups were analysed, similar findings in terms of median overall survival were observed in all groups (good, intermediate, poor cytogenetics, including monosomy 7).
Pri bolnikih z eno ali več citogenetskih abnormalnosti ob izhodišču je bil odstotek bolnikov z bistvenim citogenetskim odzivom podoben v skupini z azacitidinom in v kombinirani skupini CCR.
When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g.
Kadar se irbesartan uporablja sočasno z nizkim odmerkom hidroklorotiazida (npr.
When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g.
Če se irbesartanu doda majhen odmerek hidroklorotiazida (npr.
When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g.
Če ti bolniki sočasno z irbesartanom jemljejo še majhen odmerek hidroklorotiazida (npr.
When it attaches to these receptors in the airways, it causes the muscles to relax, which keeps the airways open and helps with the patient’s breathing.
Salmeterol z vezavo na omenjene receptorje sprošča mišice, kar razširi dihalne poti in bolniku olajša dihanje.
When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open and helps with the patient’s breathing.
Formoterol z vezavo na omenjene receptorje sprošča mišice, kar razširi dihalne poti in bolniku olajša dihanje.
When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open and helps with the patient’s breathing.
Z vezavo na omenjene receptorje sprošča mišice, kar odpre dihalne poti in bolniku olajša dihanje.
When it happens, hair loss is pronounced (over 50%) in the majority of patients)
Kadar pride do tega, je pri večini bolnikov izpadanje las izrazito (več kot 50 %).)
When it has been agreed by the CHMP that the S-PSUR is no longer necessary, a full PSUR covering the period since the data lock point of the last routine PSUR will be submitted within a time frame to be agreed with the Rapporteur.
Ko bo CHMP odločil, da predaja S-PSUR ni več potrebna, bo v časovnem obdobju, dogovorjenem s poročevalcem, predložen celoten PSUR, ki bo pokrival obdobje od zaključenega obdobja zbiranja podatkov zadnjega rednega PSUR.
When it is appropriate to titrate down to a lower strength not available for Aerivio Spiromax, a change to an alternative fixed-dose combination of salmeterol and fluticasone propionate containing a lower dose of the inhaled corticosteroid is required.
Če je treba odmerek zmanjšati na manjšo jakost, ki je z zdravilom Aerivio Spiromax ni mogoče zagotoviti, ga je treba zamenjati za drugo zdravilo s fiksno kombinacijo odmerka salmeterola in flutikazonpropionata, ki vsebuje manjši odmerek inhalacijskega kortikosteroida.
When it is appropriate to titrate down to a lower strength not available for Aerivio Spiromax, a change to an alternative fixed-dose combination of salmeterol and fluticasone propionate containing a lower dose of the inhaled corticosteroid is required.
Če je treba odmerek zmanjšati na manjšo jakost, ki je z zdravilom Airexar Spiromax ni mogoče zagotoviti, ga je treba zamenjati za drugo zdravilo s fiksno kombinacijo odmerka salmeterola in flutikazonpropionata, ki vsebuje manjši odmerek inhalacijskega kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for BiResp Spiromax, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kadar je primerno titrirati zdravilo na nižji odmerek, kot je na voljo pri zdravilu BiResp Spiromax, je potreben prehod na alternativno fiksno kombinacijo budezonida in formoterolijevega, ki vsebuje nižje odmerke inhalacijskega kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for BiResp Spiromax, a change to an alternative fixed–dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kadar je primerno titrirati zdravilo na nižji odmerek, kot je na voljo pri zdravilu BiResp Spiromax, je potreben prehod na alternativno fiksno kombinacijo budezonida in formoterolijevega fumarata, ki vsebuje nižje odmerke inhalacijskega kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for Budesonide/Formoterol Teva Pharma B.V., a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kadar je primerno titrirati zdravilo na nižji odmerek, kot je na voljo pri zdravilu Budezonid/formoterol Teva Pharma B.V., je potreben prehod na alternativno fiksno kombinacijo budezonida in formoterolijevega, ki vsebuje nižje odmerke inhalacijskega kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for Budesonide/Formoterol Teva Pharma B.V., a change to an alternative fixed–dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kadar je primerno titrirati zdravilo na nižji odmerek, kot je na voljo pri zdravilu Budezonid/formoterol Teva Pharma B.V., je potreben prehod na alternativno fiksno kombinacijo budezonida in formoterolijevega fumarata, ki vsebuje nižje odmerke inhalacijskega kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for Budesonide/Formoterol Teva, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kadar je primerno titrirati zdravilo na nižji odmerek, kot je na voljo pri zdravilu Budezonid/formoterol Teva, je potreben prehod na alternativno fiksno kombinacijo budezonida in formoterolijevega fumarata, ki vsebuje nižje odmerke inhalacijskega kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for Budesonide/Formoterol Teva, a change to an alternative fixed–dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kadar je primerno titrirati zdravilo na nižji odmerek, kot je na voljo pri zdravilu Budezonid/formoterol Teva, je potreben prehod na alternativno fiksno kombinacijo budezonida in formoterolijevega fumarata, ki vsebuje nižje odmerke inhalacijskega kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for DuoResp Spiromax, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kadar je primerno titrirati zdravilo na nižji odmerek, kot je na voljo pri zdravilu DuoResp Spiromax, je potreben prehod na alternativno fiksno kombinacijo budezonida in formoterolijevega, ki vsebuje nižje odmerke inhalacijskega kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for DuoResp Spiromax, a change to an alternative fixed–dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kadar je primerno titrirati zdravilo na nižji odmerek, kot je na voljo pri zdravilu DuoResp Spiromax, je potreben prehod na alternativno fiksno kombinacijo budezonida in formoterolijevega fumarata, ki vsebuje nižje odmerke inhalacijskega kortikosteroida.
When it is blocked, a substance called ‘cyclic guanine monophosphate’ (cGMP) cannot be broken down, so that it remains in the vessels where it causes relaxation and widening of the blood vessels.
Če je snov, imenovana „ciklični gvanozinmonofosfat“ (cGMP), zavirana, se ne more razgraditi in ostane v žilah, kjer povzroči, da se te sprostijo in razširijo.
When it is expected that higher levels of maternally derived antibodies against PCV2 are present, the following schedule of two vaccinations is advised: the first injection (2 ml) can be given from an age of 3–5 days, the second injection (2 ml) 2–3 weeks later.
Če je pričakovana raven materinih protiteles proti PCV2 višja, cepimo dvakrat po naslednji shemi: prvi odmerek (2 ml) lahko damo od starosti 3 do 5 dni, drugega (2 ml) pa 2 do 3 tedne pozneje.
When it is given during an angioedema attack, conestat alfa stops this excessive activity, helping to relieve the patient’s symptoms.
Če dajemo konestat alfa med napadom angioedema, ta ustavi prekomerno delovanje in pomaga lajšati bolnikove simptome.
When it is given to a cow, the animal’s immune system recognises the bacteria as ‘foreign’ and makes antibodies against them.
Če cepivo damo kravi, njen imunski sistem prepozna bakterije kot „tuje“ in začne tvoriti protitelesa proti njim.
When it is given to birds, the animals’ immune systems (their natural defences) learn how to make antibodies (a special type of protein) to fight the virus.
Ko ga ptice prejmejo, se imunski sistem teh živali (njihov naravni obrambni mehanizem) nauči tvoriti protitelesa (posebno vrsto beljakovine) za boj proti virusu.
When it is given to cattle and sheep, the animals’ immune system recognises the virus as ‘foreign’ and produce antibodies against it.
Ko govedo ali ovco cepimo, imunski sistem živali prepozna virus kot „tujek“ in proti njemu izdela protitelesa.
When it is given to cattle and sheep, the animals’ immune system recognises the virus as ‘foreign’ and produces antibodies against it.
Ko govedo in ovce cepimo, imunski sistem živali prepozna virus kot „tujek“ in proti njemu razvije protitelesa.
When it is given to cattle or sheep, the animals’ immune system recognises the virus as foreign and makes antibodies against it.
Ko govedo ali ovce prejmejo cepivo, imunski sistem živali prepozna virus kot „tujek“ in začne proti njemu tvoriti protitelesa.
When it is given to cattle, the animals’
Ob ponovni izpostavitvi
When it is given to cattle, the immune system recognises the viruses as ‘foreign’ and makes antibodies against them.
Ko govedo prejme cepivo, imunski sistem virus prepozna kot „tujek“ in proti njemu razvije protitelesa.
When it is given to cattle, the immune system recognises the viruses as ‘foreign’ and makes antibodies against them.
Ko govedo prejme cepivo, imunski sistem viruse prepozna kot „tujke“ in proti njim razvije protitelesa.
When it is given to chickens and ducks, the birds’ immune system (their natural defence mechanism) makes antibodies (a special type of protein) to fight the disease.
Po prejetju cepiva začne imunski sistem (naravni obrambni mehanizem) piščancev in rac tvoriti protitelesa (posebno vrsto beljakovine) za boj proti bolezni.
When it is given to chickens, the birds’ immune system (their natural defence mechanism) learns how to make antibodies (a special type of protein) to fight the disease.
Ko ga piščanec prejme, se imunski sistem ptic (njihov naravni obrambni mehanizem) nauči tvoriti protitelesa (posebno vrsto beljakovine) za boj proti bolezni.
When it is given to piglets (or their mothers), the immune system recognises the virus as ‘foreign’ and makes antibodies against it.
Ko pujske (ali njihove matere) cepimo, imunski sistem virus prepozna kot „tujek“ in proti njemu razvije protitelesa.
When it is given to rabbits the immune system recognises the myxoma and RHD materials as ‘foreign’ and makes antibodies against them.
Pri cepljenju kuncev njihov imunski sistem viruse miksoma in RHD snovi prepozna kot „tujke“ in proti njim razvije protitelesa.
When it is given to rabbits the immune system recognises the virus as ‘foreign’ and makes antibodies against it.
Ko kunci prejmejo cepivo, imunski sistem prepozna virus kot „tujek“ in začne proti njemu tvoriti protitelesa.
When it is given to sheep and cattle, the animals’ immune systems recognise the viruses as ‘foreign’ and make antibodies against them.
Ko ovce in govedo prejmejo cepivo, njihov imunski sistem viruse prepozna kot „tujke“ in proti njim razvije protitelesa.
When it is given to sheep, the immune system recognises the viruses as ‘foreign’ and makes antibodies against them.
Ko ovca prejme cepivo, imunski sistem virus prepozna kot „tujek“ in proti njemu razvije protitelesa.
When it is given to sheep, the immune system recognises the viruses as ‘foreign’ and makes antibodies against them.
Ko ovca prejme cepivo, imunski sistem viruse prepozna kot „tujke“ in proti njim razvije protitelesa.
When it is given to sows, the animal’s immune system (their natural defence mechanism) learns how to make antibodies (a special type of protein) to fight the disease.
Ko svinja prejme zdravilo, se imunski sistem (naravni obrambni mehanizem) živali nauči izdelovati protitelesa (posebno vrsto beljakovin) za boj proti bolezni.
When it is illuminated with laser light of a specific wavelength, it is activated and reacts with oxygen in the cells to create a highly reactive and toxic type of oxygen called ‘singlet oxygen’.
Ko ga osvetlimo z lasersko svetlobo določene valovne dolžine, se porfimer aktivira in reagira s kisikom v celicah, pri čemer se tvori zelo reaktivna in strupena oblika kisika, imenovana singletni kisik.
When it is necessary to administer radioactive medicinal products to women of childbearing potential, information should always be sought about pregnancy.
Kadar je treba uporabiti radioaktivna zdravila pri ženskah v rodnem obdobju, moramo vedno pridobiti podatke o nosečnosti.
When it is time for your next routine dose, go to Section 3, Step 1, and repeat Steps 1 - 7.
Ko je čas za vaš naslednji redni odmerek, pojdite na Poglavje 3, Korak 1 ter ponovite Korake 1–7.
When it is used with meals, 50 to 70% of the insulin requirement may be provided by NovoRapid and the remainder by an intermediate or long-acting insulin.
Kadar se uporablja s hrano, lahko zdravilo NovoRapid zadovolji 50–70 % potrebe po insulinu, preostanek pa srednjedolgodelujoči ali dolgodelujoči insulin.